BioMark Diagnostics Inc.
BMKDF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $154 | $163 | $153 | $44 |
| % Growth | -5.5% | 6.3% | 249.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $154 | $163 | $153 | $44 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $696 | $651 | $546 | $498 |
| G&A Expenses | $999 | $722 | $959 | $565 |
| SG&A Expenses | $999 | $722 | $959 | $565 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $367 | $106 | $381 | $385 |
| Operating Expenses | $2,062 | $1,479 | $1,886 | $1,447 |
| Operating Income | -$1,908 | -$1,316 | -$1,732 | -$1,403 |
| % Margin | -1,237.3% | -806.1% | -1,128.4% | -3,193.7% |
| Other Income/Exp. Net | -$19 | -$112 | -$110 | -$51 |
| Pre-Tax Income | -$1,927 | -$1,427 | -$1,842 | -$1,454 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,927 | -$1,427 | -$1,842 | -$1,454 |
| % Margin | -1,249.7% | -874.5% | -1,200.2% | -3,309.4% |
| EPS | -0.02 | -0.017 | -0.022 | -0.02 |
| % Growth | -19.8% | 25.1% | -10.9% | – |
| EPS Diluted | -0.02 | -0.017 | -0.022 | -0.02 |
| Weighted Avg Shares Out | 90,925 | 85,238 | 82,778 | 72,314 |
| Weighted Avg Shares Out Dil | 90,925 | 85,238 | 82,778 | 72,314 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $4 | $0 | $0 |
| Interest Expense | $62 | $115 | $110 | $50 |
| Depreciation & Amortization | $401 | $393 | $386 | $180 |
| EBITDA | -$1,464 | -$919 | -$1,346 | -$1,225 |
| % Margin | -949.6% | -563.1% | -876.8% | -2,787.4% |